Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 1,327 INR
Change Today +31.05 / 2.40%
Volume 845.5K
WPL On Other Exchanges
Natl India
As of 5:58 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

wockhardt ltd (WPL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - 2,000
52 Week Low
09/4/14 - 688.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WOCKHARDT LTD (WPL)

Related News

No related news articles were found.

wockhardt ltd (WPL) Related Businessweek News

No Related Businessweek News Found

wockhardt ltd (WPL) Details

Wockhardt Limited, a pharmaceutical and biotechnology company, together with its subsidiaries, manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines in India, the United States, Europe, and other countries. It provides pharmaceutical products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; and value-added generics. Its biopharmaceutical products include Glargine that is recombinant insulin; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing and packaging services for sterile injectables, lyophilisation, solid dose, liquids/ointments/creams, sachets and powders, and specialized products; API manufacturing services; and contract research services. Its research activities comprise pharmaceutical formulations, biopharmaceutical bulk and formulations, novel drug delivery systems, new drug discovery programs, and process engineering for APIs. The company develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Khorakiwala Holdings and Investments Private Limited.

Founded in 1999

wockhardt ltd (WPL) Top Compensated Officers

Managing Director, Executive Director, Member...
Total Annual Compensation: 11.9M
Founder, Executive Chairman, Group Chief Exec...
Total Annual Compensation: 11.9M
Executive Director, Member of Share Allotment...
Total Annual Compensation: 11.9M
Compensation as of Fiscal Year 2015.

wockhardt ltd (WPL) Key Developments

Wockhardt Ltd to Recall Drugs from US

Wockhardt Ltd. informed that has earlier decided to recall, as a part of remedial measure the remaining batches in the US market that were manufactured prior to US FDA Import Alerts even though there was no evidence of risk to patient safety from these products. The same was informed to the Stock Exchanges on 28th April, 2015 by the company. (Acknowledged copy of the letter is enclosed for reference). The recall stated in the news item forms part of the same. As a part of standard practice, the Company has to inform to US FDA periodically the products actually received from the trade against such recall. Such periodic returns of products are reported by the media based on such information submitted to US FDA by the company from time to time even though they are not additional recalls. The company has policy to recognise and provide in the books of accounts such recalls and accordingly the same has been duly recognised in the published financial results of the company. The impact on the revenue from any future returns of the products is not expected to be significant. The company keeps the exchange informed about events, information etc. including price sensitive information in accordance with regulatory requirements.

Wockhardt Ltd. Proposes to Declare Dividend on Preference Shares and to Approve Dividend for Equity Shares During the Financial Year 2014-15

Wockhardt Limited proposed to declare dividend on preference shares at the rate of 0.01%, absorbing a sum of INR 298,557 and to confirm the payment of interim dividend aggregating to INR 20 per equity share of face value of INR 5 each (400%) made during the fiscal 2015.

Wockhardt Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Wockhardt Ltd. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, net sales /income from operations was INR 11,406.5 million compared to INR 9,911.9 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 1,326.1 million compared to INR 261.7 million a year ago. Profit from ordinary activities before tax was INR 1,544.3 million against INR 251.4 million a year ago. Net profit after tax, minority interest and shares of profit of associates was INR 1,142.0 million or INR 10.26 per diluted share compared to net profit of INR 199.5 million or INR 1.80 per diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WPL:IN 1,327.00 INR +31.05

WPL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,865 INR +23.35
Cipla Ltd/India 661.60 INR +13.30
Endo International PLC $74.96 USD +1.48
Ipca Laboratories Ltd 789.05 INR -11.85
Torrent Pharmaceuticals Ltd 1,650 INR +24.40
View Industry Companies

Industry Analysis


Industry Average

Valuation WPL Industry Range
Price/Earnings 27.8x
Price/Sales 3.0x
Price/Book 4.0x
Price/Cash Flow 21.4x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WOCKHARDT LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at